NKT cell subsets can exert opposing effects in autoimmunity, tumor surveillance and inflammation

Current Immunology Reviews

Volumn 8, Issue 4, 2012, Pages 287-296

  Viale, Rachael ^a   Ware, Randle ^a   Maricic, Igor ^a   Chaturvedi, Varun ^a   Kumar, Vipin ^a  

^a TORREY PINES INSTITUTE FOR MOLECULAR STUDIES   (United States)

Author keywords

Cancer; CD1; Glycolipids; NKT cells; Sulfatide; Th1 Th17

Indexed keywords

ALPHA GALACTOSYLCERAMIDE; GALACTOSYLCERAMIDE; GAMMA INTERFERON; SULFATIDE;

ALLERGIC ENCEPHALOMYELITIS; ARTHRITIS; ARTICLE; ASTHMA; AUTOIMMUNE DISEASE; AUTOIMMUNITY; CD4+ T LYMPHOCYTE; CELL ACTIVATION; CYTOKINE RELEASE; HUMAN; IMMUNOSURVEILLANCE; INFLAMMATORY DISEASE; INSULIN DEPENDENT DIABETES MELLITUS; LIVER DISEASE; MULTIPLE SCLEROSIS; MYASTHENIA GRAVIS; NATURAL KILLER T CELL; NONHUMAN; PRIMARY BILIARY CIRRHOSIS; PRIORITY JOURNAL; REPERFUSION INJURY; RHEUMATOID ARTHRITIS; SYSTEMIC LUPUS ERYTHEMATOSUS;

EID: 84872586056     PISSN: 15733955     EISSN: 1875631X     Source Type: Journal    
DOI: 10.2174/157339512804806224     Document Type: Article

References (118)

1. Arrenberg P, Halder R, Kumar V. Cross-regulation between distinct natural killer T cell subsets influences immune response to self and foreign antigens. J Cell Physiol 2009; 218(2): 246-50.
2. Bendelac A, Savage PB, Teyton L. The biology of NKT cells. Annu Rev Immunol 2007; 25: 297-336.
3. Godfrey DI, Kronenberg M. Going both ways: immune regulation via CD1d-dependent NKT cells. J Clin Invest 2004; 114(10): 1379-88.
4. Godfrey DI, Stankovic S, Baxter AG. Raising the NKT cell family. Nat Immunol 2010; 11(3): 197-206.
5. Godfrey DI, Pellicci DG, Patel O, Kjer-Nielsen L, McCluskey J, Rossjohn J. Antigen recognition by CD1d-restricted NKT T cell receptors. Semin Immunol 2009; 22(2): 61-7.
6. Snyder-Cappione JE, Tincati C, Eccles-James IG, et al. A comprehensive ex vivo functional analysis of human NKT cells reveals production of MIP1-alpha and MIP1-beta, a lack of IL-17, and a Th1-bias in males. PLoS One 2010; 5(11): e15412.
7. Jahng AW, Maricic I, Pedersen B, et al. Activation of natural killer T cells potentiates or prevents experimental autoimmune encephalomyelitis. J Exp Med 2001; 194(12): 1789-99.
8. Benlagha K, Weiss A, Beavis A, Teyton L, Bendelac A. In vivo identification of glycolipid antigen-specific T cells using fluorescent CD1d tetramers. J Exp Med 2000; 191(11): 1895-903.
9. Chiu YH, Jayawardena J, Weiss A, et al. Distinct subsets of CD1drestricted T cells recognize self-antigens loaded in different cellular compartments. J Exp Med 1999; 189(1): 103-10.
10. Matsuda JL, Naidenko OV, Gapin L, et al. Tracking the response of natural killer T cells to a glycolipid antigen using CD1d tetramers. J Exp Med 2000; 192(5): 741-54.
11. Crowe NY, Uldrich AP, Kyparissoudis K, et al. Glycolipid antigen drives rapid expansion and sustained cytokine production by NK T cells. J Immunol 2003; 171(8): 4020-7.
12. Kawano T, Cui J, Koezuka Y, et al. CD1d-restricted and TCRmediated activation of valpha14 NKT cells by glycosylceramides. Science 1997; 278(5343): 1626-9.
13. Wilson SB, Delovitch TL. Janus-like role of regulatory iNKT cells in autoimmune disease and tumour immunity. Nat Rev Immunol 2003; 3(3): 211-22.
14. Cardell S, Tangri S, Chan S, Kronenberg M, Benoist C, Mathis D. CD1-restricted CD4+ T cells in major histocompatibility complex class II-deficient mice. J Exp Med 1995; 182(4): 993-1004.
15. Godfrey DI, MacDonald HR, Kronenberg M, Smyth MJ, Van Kaer L. NKT cells: what's in a name? Nat Rev Immunol 2004; 4(3): 231-7.
16. Park SH, Weiss A, Benlagha K, Kyin T, Teyton L, Bendelac A. The mouse CD1d-restricted repertoire is dominated by a few autoreactive T cell receptor families. J Exp Med 2001; 193(8): 893-904.
17. Exley MA, Tahir SM, Cheng O, et al. A major fraction of human bone marrow lymphocytes are Th2-like CD1d-reactive T cells that can suppress mixed lymphocyte responses. J Immunol 2001; 167(10): 5531-4.
18. Jahng A, Maricic I, Aguilera C, Cardell S, Halder RC, Kumar V. Prevention of autoimmunity by targeting a distinct, noninvariant CD1d-reactive T cell population reactive to sulfatide. J Exp Med 2004; 199(7): 947-57.
19. Arrenberg P, Halder R, Dai Y, Maricic I, Kumar V. Oligoclonality and innate-like features in the TCR repertoire of type II NKT cells reactive to a beta-linked self-glycolipid. Proc Natl Acad Sci USA 2010; 107(24): 10984-9.
20. Fuss IJ, Heller F, Boirivant M, et al. Nonclassical CD1d-restricted NK T cells that produce IL-13 characterize an atypical Th2 response in ulcerative colitis. J Clin Invest 2004; 113(10): 1490-7.
21. Girardi E, Maricic I, Wang J, et al. Type II natural killer T cells use features of both innate-like and conventional T cells to recognize sulfatide self antigens. Nat Immunol 2012; 13(9): 851-6.
22. Zajonc DM, Maricic I, Wu D, et al. Structural basis for CD1d presentation of a sulfatide derived from myelin and its implications for autoimmunity. J Exp Med 2005; 202(11): 1517-26.
23. Shinkai K, Locksley RM. CD1, tuberculosis, and the evolution of major histocompatibility complex molecules. J Exp Med 2000; 191(6): 907-14.
24. Wu L, Van Kaer L. Natural killer T cells and autoimmune disease. Curr Mol Med 2009; 9(1): 4-14.
25. Ortaldo JR, Young HA, Winkler-Pickett RT, Bere EW, Jr., Murphy WJ, Wiltrout RH. Dissociation of NKT stimulation, cytokine induction, and NK activation in vivo by the use of distinct TCRbinding ceramides. J Immunol 2004; 172(2): 943-53.
26. Rhost S, Lofbom L, Rynmark BM, et al. Identification of novel glycolipid ligands activating a sulfatide reactive, CD1d-restricted, type II natural killer T lymphocyte. Eur J Immunol 2012. [Epub ahead of print].
27. Hayakawa Y, Rovero S, Forni G, Smyth MJ. Alphagalactosylceramide (KRN7000) suppression of chemical-and oncogene-dependent carcinogenesis. Proc Natl Acad Sci USA 2003; 100(16): 9464-9.
28. Zhou D, Mattner J, Cantu C, 3rd, et al. Lysosomal glycosphingolipid recognition by NKT cells. Science 2004; 306(5702): 1786-9.
29. Chang DH, Deng H, Matthews P, et al. Inflammation-associated lysophospholipids as ligands for CD1d-restricted T cells in human cancer. Blood 2008; 112(4): 1308-16.
30. Halder RC, Jahng A, Maricic I, Kumar V. Mini review: immune response to myelin-derived sulfatide and CNS-demyelination. Neurochem Res 2007; 32(2): 257-62.
31. Subramanian L, Blumenfeld H, Tohn R, et al. NKT cells stimulated by long Fatty acyl chain sulfatides significantly reduces the incidence of type 1 diabetes in nonobese diabetic mice. PLoS One 2012; 7(5): e37771.
32. Shamshiev A, Donda A, Prigozy TI, et al. The alphabeta T cell response to self-glycolipids shows a novel mechanism of CD1b loading and a requirement for complex oligosaccharides. Immunity 2000; 13(2): 255-64.
33. Ambrosino E, Terabe M, Halder RC, et al. Cross-regulation between type I and type II NKT cells in regulating tumor immunity: a new immunoregulatory axis. J Immunol 2007; 179(8): 5126-36.
34. Halder RC, Aguilera C, Maricic I, Kumar V. Type II NKT cellmediated anergy induction in type I NKT cells prevents inflammatory liver disease. J Clin Invest 2007; 117(8): 2302-12.
35. Peters A, Lee Y, Kuchroo VK. The many faces of Th17 cells. Curr Opin Immunol 2011; 23(6): 702-6.
36. Charlton B, Lafferty KJ. The Th1/Th2 balance in autoimmunity. Curr Opin Immunol 1995; 7(6): 793-8.
37. Cua DJ, Sherlock J, Chen Y, et al. Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain. Nature 2003; 421(6924): 744-8.
38. Marwaha AK, Leung NJ, McMurchy AN, Levings MK. TH17 cells in autoimmunity and immunodeficiency: protective or pathogenic? Front Immunol 2012; 3: 129.
39. Uemura Y, Liu TY, Narita Y, et al. Cytokine-dependent modification of IL-12p70 and IL-23 balance in dendritic cells by ligand activation of Valpha24 invariant NKT cells. J Immunol 2009; 183(1): 201-8.
40. Illes Z, Kondo T, Newcombe J, Oka N, Tabira T, Yamamura T. Differential expression of NK T cell V alpha 24J alpha Q invariant TCR chain in the lesions of multiple sclerosis and chronic inflammatory demyelinating polyneuropathy. J Immunol 2000; 164(8): 4375-81.
41. van der Vliet HJ, von Blomberg BM, Nishi N, et al. Circulating V(alpha24+) Vbeta11+ NKT cell numbers are decreased in a wide variety of diseases that are characterized by autoreactive tissue damage. Clin Immunol 2001; 100(2): 144-8.
42. Gigli G, Caielli S, Cutuli D, Falcone M. Innate immunity modulates autoimmunity: type 1 interferon-beta treatment in multiple sclerosis promotes growth and function of regulatory invariant natural killer T cells through dendritic cell maturation. Immunology 2007; 122(3): 409-17.
43. Zamvil SS, Steinman L. The T lymphocyte in experimental allergic encephalomyelitis. Annu Rev Immunol 1990; 8: 579-621.
44. Miyamoto K, Miyake S, Yamamura T. A synthetic glycolipid prevents autoimmune encephalomyelitis by inducing TH2 bias of natural killer T cells. Nature 2001; 413(6855): 531-4.
45. Furlan R, Bergami A, Cantarella D, et al. Activation of invariant NKT cells by alphaGalCer administration protects mice from MOG35-55-induced EAE: critical roles for administration route and IFN-gamma. Eur J Immunol 2003; 33(7): 1830-8.
46. Mars LT, Laloux V, Goude K, et al. Cutting edge: V alpha 14-J alpha 281 NKT cells naturally regulate experimental autoimmune encephalomyelitis in nonobese diabetic mice. J Immunol 2002; 168(12): 6007-11.
47. Singh AK, Wilson MT, Hong S, et al. Natural killer T cell activation protects mice against experimental autoimmune encephalomyelitis. J Exp Med 2001; 194(12): 1801-11.
48. Teige A, Teige I, Lavasani S, et al. CD1-dependent regulation of chronic central nervous system inflammation in experimental autoimmune encephalomyelitis. J Immunol 2004; 172(1): 186-94.
49. Kukreja A, Cost G, Marker J, et al. Multiple immuno-regulatory defects in type-1 diabetes. J Clin Invest 2002; 109(1): 131-40.
50. Wilson SB, Kent SC, Patton KT, et al. Extreme Th1 bias of invariant Valpha24JalphaQ T cells in type 1 diabetes. Nature 1998; 391(6663): 177-81.
51. Oikawa Y, Shimada A, Yamada S, et al. High frequency of valpha24(+) vbeta11(+) T-cells observed in type 1 diabetes. Diabetes Care 2002; 25(10): 1818-23.
52. Alyanakian MA, Grela F, Aumeunier A, et al. Transforming growth factor-beta and natural killer T-cells are involved in the protective effect of a bacterial extract on type 1 diabetes. Diabetes 2006; 55(1): 179-85.
53. Falcone M, Yeung B, Tucker L, Rodriguez E, Sarvetnick N. A defect in interleukin 12-induced activation and interferon gamma secretion of peripheral natural killer T cells in nonobese diabetic mice suggests new pathogenic mechanisms for insulin-dependent diabetes mellitus. J Exp Med 1999; 190(7): 963-72.
54. Hong S, Wilson MT, Serizawa I, et al. The natural killer T-cell ligand alpha-galactosylceramide prevents autoimmune diabetes in non-obese diabetic mice. Nat Med 2001; 7(9): 1052-6.
55. Shi FD, Flodstrom M, Balasa B, et al. Germ line deletion of the CD1 locus exacerbates diabetes in the NOD mouse. Proc Natl Acad Sci USA 2001; 98(12): 6777-82.
56. Wang B, Geng YB, Wang CR. CD1-restricted NK T cells protect nonobese diabetic mice from developing diabetes. J Exp Med 2001; 194(3): 313-20.
57. Cardell SL. The natural killer T lymphocyte: a player in the complex regulation of autoimmune diabetes in non-obese diabetic mice. Clin Exp Immunol 2006; 143(2): 194-202.
58. Hammond KJ, Poulton LD, Palmisano LJ, Silveira PA, Godfrey DI, Baxter AG. alpha/beta-T cell receptor (TCR)+CD4-CD8-(NKT) thymocytes prevent insulin-dependent diabetes mellitus in nonobese diabetic (NOD)/Lt mice by the influence of interleukin (IL)-4 and/or IL-10. J Exp Med 1998; 187(7): 1047-56.
59. Caielli S, Sorini C, Falcone M. The dangerous liaison between iNKT cells and dendritic cells: does it prevent or promote autoimmune diseases? Autoimmunity 2010; 44(1): 11-22.
60. Lee PT, Benlagha K, Teyton L, Bendelac A. Distinct functional lineages of human V(alpha)24 natural killer T cells. J Exp Med 2002; 195(5): 637-41.
61. Pakala SV, Kurrer MO, Katz JD. T helper 2 (Th2) T cells induce acute pancreatitis and diabetes in immune-compromised nonobese diabetic (NOD) mice. J Exp Med 1997; 186(2): 299-306.
62. Kojo S, Adachi Y, Keino H, Taniguchi M, Sumida T. Dysfunction of T cell receptor AV24AJ18+, BV11+ double-negative regulatory natural killer T cells in autoimmune diseases. Arthritis Rheum 2001; 44(5): 1127-38.
63. Maeda T, Keino H, Asahara H, Taniguchi M, Nishioka K, Sumida T. Decreased TCR AV24AJ18+ double-negative T cells in rheumatoid synovium. Rheumatology (Oxford) 1999; 38(2): 186-8.
64. Luross JA, Williams NA. The genetic and immunopathological processes underlying collagen-induced arthritis. Immunology 2001; 103(4): 407-16.
65. Chiba A, Oki S, Miyamoto K, Hashimoto H, Yamamura T, Miyake S. Suppression of collagen-induced arthritis by natural killer T cell activation with OCH, a sphingosine-truncated analog of alphagalactosylceramide. Arthritis Rheum 2004; 50(1): 305-13.
66. Suzuki S, Utsugisawa K, Iwasa K, et al. Autoimmunity to endoplasmic reticulum chaperone GRP94 in myasthenia gravis. J Neuroimmunol 2011; 237(1-2): 87-92.
67. Liu R, La Cava A, Bai XF, et al. Cooperation of invariant NKT cells and CD4+CD25+ T regulatory cells in the prevention of autoimmune myasthenia. J Immunol 2005; 175(12): 7898-904.
68. Beaudoin L, Laloux V, Novak J, Lucas B, Lehuen A. NKT cells inhibit the onset of diabetes by impairing the development of pathogenic T cells specific for pancreatic beta cells. Immunity 2002; 17(6): 725-36.
69. Gigante A, Gasperini ML, Afeltra A, et al. Cytokines expression in SLE nephritis. Eur Rev Med Pharmacol Sci 2011; 15(1): 15-24.
70. Akahoshi M, Nakashima H, Tanaka Y, et al. Th1/Th2 balance of peripheral T helper cells in systemic lupus erythematosus. Arthritis Rheum 1999; 42(8): 1644-8.
71. Wong CK, Lit LC, Tam LS, Li EK, Wong PT, Lam CW. Hyperproduction of IL-23 and IL-17 in patients with systemic lupus erythematosus: implications for Th17-mediated inflammation in auto-immunity. Clin Immunol 2008; 127(3): 385-93.
72. Wong CK, Ho CY, Li EK, Lam CW. Elevation of proinflammatory cytokine (IL-18, IL-17, IL-12) and Th2 cytokine (IL-4) concentrations in patients with systemic lupus erythematosus. Lupus 2000; 9(8): 589-93.
73. Chuang YP, Wang CH, Wang NC, Chang DM, Sytwu HK. Modulatory function of invariant natural killer T cells in systemic lupus erythematosus. Clin Dev Immunol 2012; 2012: 478429.
74. Singh AK, Yang JQ, Parekh VV, et al. The natural killer T cell ligand alpha-galactosylceramide prevents or promotes pristaneinduced lupus in mice. Eur J Immunol 2005; 35(4): 1143-54.
75. Takahashi T, Strober S. Natural killer T cells and innate immune B cells from lupus-prone NZB/W mice interact to generate IgM and IgG autoantibodies. Eur J Immunol 2008; 38(1): 156-65.
76. Wermeling F, Lind SM, Jordo ED, Cardell SL, Karlsson MC. Invariant NKT cells limit activation of autoreactive CD1d-positive B cells. J Exp Med 2010; 207(5): 943-52.
77. Zeng D, Dick M, Cheng L, et al. Subsets of transgenic T cells that recognize CD1 induce or prevent murine lupus: role of cytokines. J Exp Med 1998; 187(4): 525-36.
78. Yang YF, Tomura M, Ono S, Hamaoka T, Fujiwara H. Requirement for IFN-gamma in IL-12 production induced by collaboration between v(alpha)14(+) NKT cells and antigenpresenting cells. Int Immunol 2000; 12(12): 1669-75.
79. Chan G, Hanke T, Fischer KD. Vav-1 regulates NK T cell development and NK cell cytotoxicity. Eur J Immunol 2001; 31(8): 2403-10.
80. Forestier C, Molano A, Im JS, et al. Expansion and hyperactivity of CD1d-restricted NKT cells during the progression of systemic lupus erythematosus in (New Zealand Black x New Zealand White)F1 mice. J Immunol. 2005; 175(2): 763-70.
81. Diao H, Kon S, Iwabuchi K, et al. Osteopontin as a mediator of NKT cell function in T cell-mediated liver diseases. Immunity 2004; 21(4): 539-50.
82. Takeda K, Hayakawa Y, Van Kaer L, Matsuda H, Yagita H, Okumura K. Critical contribution of liver natural killer T cells to a murine model of hepatitis. Proc Natl Acad Sci USA 2000; 97(10): 5498-503.
83. Akbari O, Stock P, Meyer E, et al. Essential role of NKT cells producing IL-4 and IL-13 in the development of allergen-induced airway hyperreactivity. Nat Med 2003; 9(5): 582-8.
84. Osman Y, Kawamura T, Naito T, et al. Activation of hepatic NKT cells and subsequent liver injury following administration of alphagalactosylceramide. Eur J Immunol 2000; 30(7): 1919-28.
85. Tsuneyama K, Yasoshima M, Harada K, Hiramatsu K, Gershwin ME, Nakanuma Y. Increased CD1d expression on small bile duct epithelium and epithelioid granuloma in livers in primary biliary cirrhosis. Hepatology 1998; 28(3): 620-3.
86. Kita H, Naidenko OV, Kronenberg M, et al. Quantitation and phenotypic analysis of natural killer T cells in primary biliary cirrhosis using a human CD1d tetramer. Gastroenterology 2002; 123(4): 1031-43.
87. Chuang YH, Lian ZX, Yang GX, et al. Natural killer T cells exacerbate liver injury in a transforming growth factor beta receptor II dominant-negative mouse model of primary biliary cirrhosis. Hepatology 2008; 47(2): 571-80.
88. Wu SJ, Yang YH, Tsuneyama K, et al. Innate immunity and primary biliary cirrhosis: activated invariant natural killer T cells exacerbate murine autoimmune cholangitis and fibrosis. Hepatology 2010; 53(3): 915-25.
89. Arrenberg P, Maricic I, Kumar V. Sulfatide-mediated activation of type II natural killer T cells prevents hepatic ischemic reperfusion injury in mice. Gastroenterology 2010; 140(2): 646-55.
90. Motohashi S, Kobayashi S, Ito T, et al. Preserved IFN-alpha production of circulating Valpha24 NKT cells in primary lung cancer patients. Int J Cancer 2002; 102(2): 159-65.
91. Dhodapkar MV, Geller MD, Chang DH, et al. A reversible defect in natural killer T cell function characterizes the progression of premalignant to malignant multiple myeloma. J Exp Med. 2003; 197(12): 1667-76.
92. Kitamura H, Iwakabe K, Yahata T, et al. The natural killer T (NKT) cell ligand alpha-galactosylceramide demonstrates its immunopotentiating effect by inducing interleukin (IL)-12 production by dendritic cells and IL-12 receptor expression on NKT cells. J Exp Med 1999; 189(7): 1121-8.
93. Tahir SM, Cheng O, Shaulov A, et al. Loss of IFN-gamma production by invariant NK T cells in advanced cancer. J Immunol 2001; 167(7): 4046-50.
94. Molling JW, Langius JA, Langendijk JA, et al. Low levels of circulating invariant natural killer T cells predict poor clinical outcome in patients with head and neck squamous cell carcinoma. J Clin Oncol 2007; 25(7): 862-8.
95. Berzofsky JA, Terabe M. NKT cells in tumor immunity: opposing subsets define a new immunoregulatory axis. J Immunol 2008; 180(6): 3627-35.
96. Renukaradhya GJ, Sriram V, Du W, Gervay-Hague J, Van Kaer L, Brutkiewicz RR. Inhibition of antitumor immunity by invariant natural killer T cells in a T-cell lymphoma model in vivo. Int J Cancer 2006; 118(12): 3045-53.
97. Smyth MJ, Thia KY, Street SE, et al. Differential tumor surveillance by natural killer (NK) and NKT cells. J Exp Med 2000; 191(4): 661-8.
98. Iwamura C, Nakayama T. Role of NKT cells in allergic asthma. Curr Opin Immunol 2010; 22(6): 807-13.
99. Umetsu DT, Dekruyff RH. Natural killer T cells are important in the pathogenesis of asthma: the many pathways to asthma. J Allergy Clin Immunol 2010; 125(5): 975-9.
100. Kim EY, Battaile JT, Patel AC, et al. Persistent activation of an innate immune response translates respiratory viral infection into chronic lung disease. Nat Med 2008; 14(6): 633-40.
101. Pichavant M, Goya S, Meyer EH, et al. Ozone exposure in a mouse model induces airway hyperreactivity that requires the presence of natural killer T cells and IL-17. J Exp Med 2008; 205(2): 385-93.
102. Meyer EH, Goya S, Akbari O, et al. Glycolipid activation of invariant T cell receptor+ NK T cells is sufficient to induce airway hyperreactivity independent of conventional CD4+ T cells. Proc Natl Acad Sci USA 2006; 103(8): 2782-7.
103. Matangkasombut P, Pichavant M, Yasumi T, et al. Direct activation of natural killer T cells induces airway hyperreactivity in nonhuman primates. J Allergy Clin Immunol 2008; 121(5): 1287-9.
104. Zhang G, Nie H, Yang J, et al. Sulfatide-activated type II NKT cells prevent allergic airway inflammation by inhibiting type I NKT cell function in a mouse model of asthma. Am J Physiol Lung Cell Mol Physiol 2011; 301(6): L975-84.
105. Kadri N, Korpos E, Gupta S, et al. CD4(+) type II NKT cells mediate ICOS and programmed death-1-dependent regulation of type 1 diabetes. J Immunol 2012; 188(7): 3138-49.
106. Francisco LM, Salinas VH, Brown KE, et al. PD-L1 regulates the development, maintenance, and function of induced regulatory T cells. J Exp Med 2009; 206(13): 3015-29.
107. Sharma MD, Baban B, Chandler P, et al. Plasmacytoid dendritic cells from mouse tumor-draining lymph nodes directly activate mature Tregs via indoleamine 2,3-dioxygenase. J Clin Invest 2007; 117(9): 2570-82.
108. Cerundolo V, Silk JD, Masri SH, Salio M. Harnessing invariant NKT cells in vaccination strategies. Nat Rev Immunol 2009; 9(1): 28-38.
109. Chan AC, Serwecinska L, Cochrane A, Harrison LC, Godfrey DI, Berzins SP. Immune characterization of an individual with an exceptionally high natural killer T cell frequency and her immediate family. Clin Exp Immunol 2009; 156(2): 238-45.
110. Berzins SP, Kyparissoudis K, Pellicci DG, et al. Systemic NKT cell deficiency in NOD mice is not detected in peripheral blood: implications for human studies. Immunol Cell Biol 2004; 82(3): 247-52.
111. Berzins SP, Smyth MJ, Baxter AG. Presumed guilty: natural killer T cell defects and human disease. Nat Rev Immunol 2011; 11(2): 131-42.
112. Borowski C, Bendelac A. Signaling for NKT cell development: the SAP-FynT connection. J Exp Med 2005; 201(6): 833-6.
113. Savage AK, Constantinides MG, Han J, et al. The transcription factor PLZF directs the effector program of the NKT cell lineage. Immunity 2008; 29(3): 391-403.
114. Bendelac A, Rivera MN, Park SH, Roark JH. Mouse CD1-specific NK1 T cells: development, specificity, and function. Annu Rev Immunol 1997; 15: 535-62.
115. Giaccone G, Punt CJ, Ando Y, et al. A phase I study of the natural killer T-cell ligand alpha-galactosylceramide (KRN7000) in patients with solid tumors. Clin Cancer Res 2002; 8(12): 3702-9.
116. Nieda M, Okai M, Tazbirkova A, et al. Therapeutic activation of Valpha24+Vbeta11+ NKT cells in human subjects results in highly coordinated secondary activation of acquired and innate immunity. Blood 2004; 103(2): 383-9.
117. Chang DH, Osman K, Connolly J, et al. Sustained expansion of NKT cells and antigen-specific T cells after injection of alphagalactosyl-ceramide loaded mature dendritic cells in cancer patients. J Exp Med. 2005; 201(9): 1503-17.
118. Ishikawa A, Motohashi S, Ishikawa E, et al. A phase I study of alpha-galactosylceramide (KRN7000)-pulsed dendritic cells in patients with advanced and recurrent non-small cell lung cancer. Clin Cancer Res 2005; 11(5): 1910-7.